Work with the Most Trusted CRO and Proceed with Your Lead Antibody with Confidence
Stand-Alone Services for Therapeutic Antibodies.
Our stand-alone offering includes studies to assess binding strength and specificity, ranging from high-throughput binding screens applying multiple target proteins, affinity ranking, species-cross reactivity studies, comprehensive evaluation of kinetic interactions with purified target proteins and target cells, as well as developability assessments, preformulation studies, storage stability studies and formulation development.
These services are powered by our scientific expertise and experience in the field, our high-end equipment enabling fast turnaround times, ensuring high-quality, reproducible data, and our responsive and transparent project management with a strong customer-first mindset.
With extensive experience across antibody modalities and target types, our scientific team creates fit-for-purpose solutions that support your project – whether you are in the screening phase, in the lead selection process, pre-formulation, or are in the need of liquid formulation development for preparing for pre-clinical or clinical advancement.
Our Stand-Alone Solutions for Your Therapeutic Antibody Projects
Target binding: Kinetics & Affinity
Target binding: Kinetics & Affinity
Binding Screens with Purified Protein and Cells
Affinity Ranking & Avidity
GCI, BLI, Flow Cytometry, scIC, heliXcyto, KinExA, strong affinity
Kinetics of Target and Target Cell Binding
heliXcyto, scIC, RT-IC, avidity
Functional Characterization
Functional Characterization
Ligand Inhibition
Flow Cytometry, heliXcyto, receptor occupancy assay
NK/T-Cell Recruiting Assay
TCEs, BSL1, BSL2, state-of-the-art kits
Signal Induction
second messenger, state-of-the-art kits
Cell Killing
ADCC, CDC
Internalization
Direct labeling (covalent), Fab-based labeling (non-covalent)
Physicochemical and Stability Assessments
Physicochemical and Stability Assessments
Multiparametric Unfolding and Aggregation Studies
DLS, nanoDSF
Conformational/Thermal and Colloidal Stability (Ton, Tm, Tagg)
DLS, nanoDSF
Self-Interaction Assessment
DLS
Low Molecular (LMW) and High Molecular Weight (HMW) Content Determination, Size
SEC MALS, HPLC, UPLC, DLS, CE-SDS
Hydrophobicity and Charge Heterogeneity Profiling, Isoelectric Focussing
HIC, IEX, HPLC, UPLC, cIEF
Polypeptide Chain Integrity, Monomer Purity
reduced CE-SDS, non-reduced CE-SDS
Services for Antibody Lead Risk Mitigation
Supporting Services
Receptor Quantification Assay
BSL1, BSL2, Flow Cytometry
Short-, Mid-, Long-Term Stablity Assessment
Accelerated stability studies, stress studies, thermal, colloidal, mechanical, oxidative, chemical stability
Stability Optimization via Design of Experiment
Pre-formulation, DSD, RSM, DoE
Target Protein Deconvolution
Protein array, ELISA
FcR and FcRn Affinities
BLI, GCI, Spectral Shift, TRIC
Developability Assessments
Stability, binding, affinity, kinetics, State-of-the-art kits, ELISA, polyreactivity, hydrophobicity, self-interaction, viscometry
Off-Target Binding Assessment
State-of-the-art kit, ELISA
Scouting for Stabilizing Buffers
Explore our off-the-shelf solution or highly customizable approach
Preformulation and Preclinical Liquid Formulation Development
Pre-formulation and Liquid Phase 1 Formulation Development
Preformulation
2bind signature buffers, Quick‘n’TidyTM approach to scout the formulation space, Design of Experiment (DoE), customized preformulation
Preclinical Liquid Formulation Development
High-concentration formulation development, low and medium concentration formulation development, manual filling
Unparalleled Precision at the Molecular Level
Stability, Size, Hydrophobicity, Charge, Chemical Modification
Deep analytical insights require a combination of high-performance separation technologies and advanced biophysical characterization. To comprehensively analyze conformational and colloidal stabilities, we monitor thermally induced unfolding, changes in the hydrodynamic radius, and the formation of soluble and structural aggregates. These reliable, highly reproducible methods detect the tiniest changes within a sample, delivering parameters like Ton, Tm, and Tagg with extraordinary precision using as little as 10-50 µg of protein, making them ideal for ranking multiple candidates or monitoring sample quality during storage, freeze-thaw cycles, and stress treatments.
To complement these biophysical insights, we utilize state-of-the-art HPLC, high-resolution UPLC, and capillary electrophoresis systems. This integrated platform allows us to precisely check molecular weights, evaluate polypeptide chain integrity, measure high-molecular-weight (HMW) and low-molecular-weight (LMW) content, and compare hydrophobicity or charge heterogeneity of sequence variants and stability samples.
Our established analytical matrix includes:
nanoDSF & DLS: For stability screening, tracking thermal unfolding Tm/Tagg/Ton alongside real-time changes in hydrodynamic radius.
SEC & SEC-MALS: For high-precision size distribution, absolute molecular weight determination, and exact quantification of monomer purity as well as HMW/LMW content.
CE-SDS (reduced / non-reduced), cIEF: For assessing size, concentration, fragmentation, structural polypeptide chain integrity and glycan occupancy, deamination, isomerization, isoelectric focussing.
HIC: For mapping hydrophobicity profiles.
IEX: For high-resolution characterization of charge heterogeneity and isoform variants.
Whether supporting early developability screens, guiding formulation development, or delivering critical read-out parameters for long-term stability studies, we leverage this high-end analytical toolkit to provide tailored, regulatory-ready insights for your candidates to understand the CQAs (critical quality attributes).
Purified Protein and Target Cells
Binding, Kinetics, Affinity, Avidity
At 2bind, we know that kinetics and affinities can be determined in multiple ways – each with a different focus, and ideally complementing one another. We perform tailored binding studies with purified recombinant proteins as well as target-expressing cells, adjusting the setup precisely to your project’s scientific requirements.
Whether you need a high-throughput screen aiming for a clear yes/no answer for hundreds of antibodies, or a detailed binding characterization of a single lead candidate, our flexible platform is engineered to match your needs. We provide deep insights into complex binding mechanisms, offering detailed kinetic measurements in both avidity-excluding (monovalent) and avidity-allowing (bivalent/multivalent) setups to accurately dissect true affinity from functional avidity.
To bridge the gap between cell-free biochemistry and physiological reality, we offer real-time kinetics on living cells, adding the native complexity of the crowded membrane surroundings to the interaction equation. For soluble targets, conversely, the physiological situation is often better reflected by in-solution affinity methods where both binding partners interact free from surface immobilization.
Our comprehensive binding and affinity matrix includes:
GCI/SPR & BLI: For high-resolution, real-time binding kinetics, association/dissociation rate constants (kon/koff), and affinity determination.
scIC (Single-Cell Interaction Chromatography): For measuring real-time binding kinetics and avidity profiles of antibodies directly on living cells.
KinExA: For ultra-precise, true in-solution affinity (Kd) measurements, ideal for tight binders or complex matrices.
Flow Cytometry: For high-throughput cellular binding validation, cross-reactivity screening, and cell-surface target engagement.
ELISA: For high-throughput, robust, gold-standard endpoint binding assays, titer determinations, and bridging studies.
Assess the Soft Skills of Your Therapeutic Candidates
Developability
Binding to its target within the envisioned affinity window and showing the functionality that is required to reach the therapeutic effect, are certainly prerequisites for a candidate to succeed in the clinic. However, a successful candidate needs to be stable during storage and handling, highly specific for its target protein, cross-reactive to the orthologue protein in the relevant species, non-immunogenic, showing ideal biodistribution and tissue penetration as well as having ideal pharmacokinetic properties. Many of these properties can be addressed directly within the screening cascade or were shown to correlate with parameters that can be measured directly.
Developability screens assess these critical “soft skills” of antibodies. Not all candidates with developability liabilities will fail in clinical development, but certain liabilities are strongly indicative of an increased risk of failure. Our platform systematically uncovers and characterizes these risks using an advanced analytical testing matrix:
Colloidal status via DLS
Thermal stability (Tm/Tagg) via nanoDSF
Size distribution via SEC-MALS
Hydrophobicity via HIC
Self-interaction via DLS
Polyreactivity & Polyspecificity assessment
Non-specific clearance risk evaluation
FcRn affinity (as an in vivo half-life indicator), and more.
If recognized early in the cycle, these risks can be successfully mitigated by sequence engineering, formulation development, and optimized storage conditions.
Measure How Your Candidate Behaves Under Stress
Storage Stability and Accelerated Stability Studies
Developing a therapeutic candidate into a successful drug product requires a deep understanding of its long-term degradation pathways. While real-time storage stability studies establish the mandatory shelf-life data under intended storage conditions, accelerated and stress stability studies act as an essential fast-track tool. By exposing molecules to controlled physical stressors – such as elevated temperatures, agitation, or freeze-thaw cycles – we deliberately provoke degradation to rapidly predict long-term behavior, identify formulation liabilities, and de-risk your IND-filing timeline.
Our stability platform tracks structural, chemical, and physical degradation pathways with extreme sensitivity, ensuring no minor change goes unnoticed.
To provide a comprehensive, regulatory-ready picture of your candidate’s stability profile, we apply our high-end analytical toolkit across all time points:
Thermal & Colloidal Drift (nanoDSF & DLS): We monitor shift profiles in thermal unfolding transitions (Tm, Ton, Tagg) and track changes in the hydrodynamic radius or the onset of aggregations directly under storage conditions.
Aggregation & Fragmentation (SEC & SEC-MALS): We precisely quantify high-molecular-weight (HMW) and low-molecular-weight (LMW) species to determine exact monomer purity over time.
Chemical & Structural Degradation (CE-SDS, cIEF, IEX & HIC): We monitor chemical stability by tracking charge heterogeneity (deamidation, C-terminal lysine clipping, isomerization) via IEX, mapping hydrophobicity shifts via HIC, and verifying polypeptide chain integrity and glycan occupancy or isoelectric focussing via CE-SDS.
- Functionality & Binding: We ensure that storage or stress conditions do not compromise therapeutic efficacy by tracking precise binding kinetics and affinity via GCI/SPR and BLI, determining complex avidity profiles using scIC, and verifying cellular target engagement as well as functional biological readouts through customized cell-based assays.
Whether you need a rapid, material-efficient screening matrix to rank early-stage candidate formulations or a comprehensive stability study to support your preclinical and clinical data packages, we tailor our study designs to your specific timelines and route of administration.
Our Dedicated Preformulation and Formulation Development Services
Buffer conditions don’t just complement the amino acid sequence, they are the unsung heroes shaping an antibody’s physicochemical properties, molecular integrity, and storage stability. By fine-tuning thermal resilience, curbing aggregation, and dialing down viscosity with smart excipients, we eliminate risks in sample shipment and storage for your preclinical and clinical studies.
As antibody-based drugs evolve into complex bi- and multispecific structures, fusions with non-antibody proteins add new functionalities, and high-concentration formulations have been trending for years, formulation optimization is no longer optional; it’s mission-critical.
At 2bind, we’re obsessed with finding your molecule’s ideal conditions. Dive into our seven AI-crafted Signature Buffers, born from evaluating 161 approved therapeutic antibody drugs, that will help and time and budget are tight. It’s like a chef’s tasting menu for proteins – meet the stars and discover your molecule’s true love:
SweetHarmony
For those who thrive in sugary bliss.
SaltyDream
When a briny embrace hits just right.
SalineBased
The reliable classic, no frills needed.
SuperSweet
Extra indulgence for the bold.
SourSalt & SourSweet
Because sometimes opposites really attract.
SkilledGues
Our ace in the hole when others fall short.
Beyond the menu, our Quick‘n’TidyTM buffer screen approach systematically probes pH variations paired with salts, sugars, sugar alcohols, amino acids, and detergents to map your molecule’s sweet spot. This is the platform solution if you need something more sophisticated. Struggling with viscosity capping concentrations? Our Fluidifiers push the limits. For tailored challenges, customized DoEs with appropriate read-out parameters deliver formulations that solve your specific problem.
Multiparametric Stability Analysis
Self-interaction and viscosity
Size Distribution, Charge heterogeneity
Preclinical Liquid Formulation Development
Transitioning a promising antibody candidate from discovery/development into early-stage toxicity and other pre-clinical tests requires more than just a stable molecule: it demands a robust, legally defensible formulation strategy. Our Preclinical Liquid Formulation Development Service is specifically engineered to de-risk this critical junction, bridging the gap between initial analytics and functionality and successful IND-filing documentation.
We believe that early-stage formulation development success is built on predictability, not unnecessary risk. That is why our approach relies strictly on conservative, industry-proven formulation strategies utilizing excipients and buffer systems well-characterized and accepted by the FDA. Instead of experimenting with unproven modalities, we focus on maximizing the potential of established frameworks.
Designed to deliver regulatory-accepted data while balancing material consumption and timeline efficiency, our platform is incorporated into our ISO 9001-certified quality management system (non-GMP). To guarantee highest-quality insights, we comprehensively track your candidates through an advanced biophysical and functional testing matrix:
Stability & Profiling: We monitor structural integrity and degradation pathways using nanoDSF and DLS for stability assessments, alongside detailed purity, fragmentation, isoelectric focussing, chemical modifications (deamination, isomerization) and aggregation profiling via SEC-MALS, HIC, IEX, cIEF, and CE-SDS.
Kinetics, Avidity & Function: Binding mechanics are deeply characterized by determining affinity and fast kinetics via GCI/SPR and BLI, measuring complex avidity (via scIC, BLI, and GCI/SPR), and evaluating cellular binding through Flow Cytometry alongside crucial functional readouts (e.g., cell death).
We can adapt to your preferred route of administration and handle challenging physical properties using specialized viscometry for high-concentration formulations tailored for subcutaneous injections, as well as low-to-medium concentration formulations for intravenously administered antibodies. We can work on antibodies, ADCs, bispecifics, nanobodies, conjugates, or mixtures.
To seamlessly support your subsequent in vivo studies, we offer flexible, small-scale manual filling services, ensuring the precise and secure preparation of your formulation batches for preclinical testing without wasting precious material.
Project onboarding and project management initiation phase
Preclinical liquid formulation development
High-concentration, low and medium concentration formulations
ISO 9001-certified quality management system
Manual filling for downstream tests like toxicological studies
Broad Expertise Across Antibody Modalities, Target Types and Disease Areas
Our antibody development services cover the full spectrum of therapeutic antibody modalities: from canonical full length IgGs and bispecific formats to antibody fragments and antibody-fusion proteins.
Leveraging our high-end equipment and deep scientific expertise, we work across diverse target types, including membrane proteins, soluble proteins, and complex multiprotein systems.
Whether your antibody is conventional or engineered for unique functions, we provide the processes, data quality, and speed to confidently advance your program.
Antibody Modalities
- IgG1, IgG4, Fc-silenced IgG
- Bispecifics
- Multispecifics
- Nanobodies
- scFvs
- Fabs
- Antibody-fusion proteins
- ADCs
Mode of Actions
- ADCC, CDC, ADCP
- Ligand inhibition
- Agonist, Antagonist
- T cell engagement
- Immune modulator
- Cytotoxicity
- Sweeping antibodies
Target types
- Membrane proteins
- Soluble proteins
- Multiprotein complexes
- Target cells
- Intrinsically disordered proteins / Amyloidogenic proteins
Disease Areas
- Cancer
- Autoimmune diseases
- Infectious diseases
- Neurological disorders
- Metabolic diseases
- Cardiovascular diseases
Get in Touch!
"We worked with the 2bind team for several years and continue to be impressed by their exceptional scientific expertise and experimental capabilities, their high flexibility regarding timelines and a great enthusiasm to explore out of the box assays. All this is paired with the team’s kind and friendly spirit, making them a real pleasure to work with."
Patrick Kunz, PhD, Director of Experimental Biophysics
Get In Touch
Planning a research project or interested in our analytical services? Get in touch with our team to discuss your requirements.
- +49 941 2000 0890
- info@2bind.com
- Im Gewerbepark D19a, 93059 Regensburg, Germany